Ocugen Inc. (OCGN): Price and Financial Metrics
OCGN Price/Volume Stats
| Current price | $0.71 | 52-week high | $2.08 |
| Prev. close | $0.80 | 52-week low | $0.52 |
| Day low | $0.68 | Volume | 5,320,700 |
| Day high | $0.77 | Avg. volume | 4,163,637 |
| 50-day MA | $0.67 | Dividend yield | N/A |
| 200-day MA | $1.02 | Market Cap | 206.25M |
OCGN Stock Price Chart Interactive Chart >
Ocugen Inc. (OCGN) Company Bio
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.
OCGN Price Returns
| 1-mo | 8.95% |
| 3-mo | N/A |
| 6-mo | -25.07% |
| 1-year | -53.90% |
| 3-year | -78.48% |
| 5-year | 153.57% |
| YTD | -11.80% |
| 2024 | 40.00% |
| 2023 | -55.77% |
| 2022 | -71.43% |
| 2021 | 148.63% |
| 2020 | 251.92% |
Loading social stream, please wait...